Claim Missing Document
Check
Articles

Found 1 Documents
Search

In Silico Evaluation of Gynura divaricata Phytochemicals as PTP1B (1T49) Inhibitors for Antidiabetic Therapy Christina JR. Esmaralda Lumbantobing; Zsa Zsa Fitria Alizar; Iffat Ayafiqoh Afif; Rahadian Zainul
EKSAKTA: Berkala Ilmiah Bidang MIPA Vol. 27 No. 05 (2026): Eksakta : Berkala Ilmiah Bidang MIPA (E-ISSN : 2549-7464) In Progress
Publisher : Faculty of Mathematics and Natural Sciences (FMIPA), Universitas Negeri Padang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24036/eksakta/vol27-iss05/736

Abstract

Effective management of type 2 diabetes mellitus (T2DM) requires therapeutic agents that can improve insulin sensitivity by modulating key molecular targets such as Protein Tyrosine Phosphatase 1B (PTP1B). However, the potential of Gynura divaricata phytochemicals as natural PTP1B inhibitors remains insufficiently characterized, despite the plant’s reported antidiabetic activity. Therefore, systematic computational screening is needed to identify promising compounds and prioritize candidates for further experimental evaluation. Such prioritization is important to reduce experimental burden and accelerate discovery of plant-derived antidiabetic leads. This study aimed to evaluate selected phytochemicals from G. divaricata as potential PTP1B inhibitors using molecular docking, drug-likeness assessment, and ADMET prediction. Docking was performed against PTP1B (PDB ID: 1T49), followed by redocking validation and pharmacokinetic analysis. Among the tested compounds, 3,5-dicaffeoylquinic acid showed the strongest binding affinity, with a docking score of −6.806 kcal/mol and an RMSD of 1.614 Å, followed by 3,4-dicaffeoylquinic acid (−6.383 kcal/mol). Redocking produced an RMSD of 1.388 Å, confirming protocol reliability. ADMET prediction showed intestinal absorption ranging from 17.004% to 77.207%, while 3,5-dicaffeoylquinic acid was predicted to be non-hepatotoxic, AMES-negative, and non-inhibitory toward major CYP enzymes. These findings support caffeoylquinic acid derivatives as promising candidates for further in vitro and in vivo antidiabetic studies.